Costanza Paoletti

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)”.

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

Biomarkers(2023)10.1080/1354750x.2023.2168063

N/A

0.587DataRank · unranked

12 citations

Adrian Nordmark, Amy Williams, Costanza Paoletti, William E. Barlow, Erin F. Cobain +11 more

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1562

N/A

0.457DataRank · unranked

20 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Molecular Oncology(2021)10.1002/1878-0261.13150

N/A

0DataRank · unranked

21 citations

Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce +27 more

Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey™ device for CTC enrichment

Lab on a Chip(2021)10.1039/d1lc00546d

N/A

0DataRank · unranked

36 citations

Jessica Antoinette Jana, Anna Kaehr, Emma Purcell, Tyler Opdycke, Costanza Paoletti +5 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384.v1

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1076

N/A

0DataRank · unranked

0 citations

William E. Barlow, Costanza Paoletti, Mattias Bergqvist, Amy Williams, Hanna Ritzén +11 more